6.91
price up icon1.02%   0.07
after-market Dopo l'orario di chiusura: 6.90 -0.010 -0.14%
loading

CorMedix Inc Borsa (CRMD) Ultime notizie

pulisher
Apr 09, 2025

RBC stays bullish on CorMedix as Q1 preliminary revenue reassures on near-term - Yahoo Finance

Apr 09, 2025
pulisher
Apr 09, 2025

CorMedix expects Q1 sales above estimates, lifts H1 outlook - MSN

Apr 09, 2025
pulisher
Apr 08, 2025

CorMedix reports preliminary Q1 revenue $39M, consensus $32.2M. - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix at Needham Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix at Needham Conference: Strategic Growth and Challenges - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Stock Rises After Preliminary Q1 Results Exceeds Expectations: Retail’s Elated - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

CRMD Soars 19.40% as CorMedix Announces Preliminary Q1 Results and Raises H1 Guidance, But Will the Momentum Continue? - RagingBull

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Inc. Raises Financial Guidance for First Half of 2025 - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Sees Q1 Net Sales of $39 Million; Boosts H1 Net Sales Guidance - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance - The Manila Times

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Logs Q1 Prel. Revenue Of $39 Mln - Nasdaq

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix reports strong preliminary Q1 revenue and EBITDA - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Smashes Expectations: $39M Q1 Revenue and Massive Guidance Boost Signals Growth Acceleration - Stock Titan

Apr 08, 2025
pulisher
Apr 02, 2025

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

CorMedix CEO Sets Stage for Strategic Updates at Elite Needham Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Mar 29, 2025

CorMedix Inc. (NASDAQ:CRMD) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025
pulisher
Mar 28, 2025

CorMedix Inc. Reports Record Q4 Earnings and Growth - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

CorMedix: A Fair-Priced Biotech Company With A Bright Future - Seeking Alpha

Mar 28, 2025
pulisher
Mar 27, 2025

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of ... - Bluefield Daily Telegraph

Mar 27, 2025
pulisher
Mar 27, 2025

Institutions along with individual investors who hold considerable shares inCorMedix Inc. (NASDAQ:CRMD) come under pressure; lose 35% of holdings value - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

CorMedix targets $50M-$60M revenue for H1 2025 with DefenCath growth - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

CorMedix Inc.'s (NASDAQ:CRMD) 35% loss last week hit both individual investors who own 56% as well as institutions - simplywall.st

Mar 27, 2025
pulisher
Mar 26, 2025

Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire

Mar 26, 2025
pulisher
Mar 26, 2025

Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

The Hidden Risks Behind CorMedix's First Profitable Quarter (NASDAQ:CRMD) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 26, 2025

CorMedix Inc (NASDAQ:CRMD) Order Delay - FXDailyReport.Com

Mar 26, 2025
pulisher
Mar 26, 2025

Long Term Trading Analysis for (CRMD) - news.stocktradersdaily.com

Mar 26, 2025
pulisher
Mar 26, 2025

INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ... By GuruFocus - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

CorMedix Inc. Achieves Profitability with DefenCath Launch - TipRanks

Mar 26, 2025
pulisher
Mar 25, 2025

Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix: Q4 Earnings Snapshot - MySA

Mar 25, 2025
pulisher
Mar 25, 2025

Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix (CRMD) Q4 2024 Earnings Call Transcript - AOL.com

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix earnings beat by $0.05, revenue topped estimates - Investing.com Canada

Mar 25, 2025
pulisher
Mar 25, 2025

Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It - Asianet Newsable

Mar 25, 2025
pulisher
Mar 25, 2025

Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix Inc. (CRMD) Takes a Hit: What’s Behind the 31% Plunge? - RagingBull

Mar 25, 2025
pulisher
Mar 25, 2025

Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off - MSN

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix shares tumble after order delay By Investing.com - Investing.com Philippines

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix shares tumble after order delay - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix Dives on Results - Baystreet.ca

Mar 25, 2025
$18.81
price up icon 4.44%
$68.57
price up icon 5.80%
$31.95
price up icon 2.37%
$23.24
price up icon 15.33%
biotechnology ONC
$230.36
price up icon 10.59%
$96.52
price up icon 3.65%
Capitalizzazione:     |  Volume (24 ore):